# Dementia

## Overview

Dementia is a clinical syndrome characterized by progressive decline in cognitive function severe enough to interfere with daily activities and independent living. It represents a major global health challenge, affecting over 55 million people worldwide. While aging is the greatest risk factor, dementia is not a normal part of aging and involves pathological processes affecting brain structure and function.

### Definition and Criteria
- **Cognitive decline**: From previous level of functioning
- **Multiple domains**: Memory, executive function, language, visuospatial, behavior
- **Functional impairment**: Interference with independence in daily activities
- **Consciousness**: Preserved alertness (distinguishes from delirium)

### Epidemiology
- **Prevalence**: ~6% of people >65 years, doubles every 5 years
- **Incidence**: 10 million new cases annually worldwide
- **Risk factors**: Age, genetics, cardiovascular disease, education
- **Economic burden**: Trillion-dollar global healthcare cost

## Classification of Dementias

### Major Types
- **Alzheimer's disease**: 60-70% of cases
- **Vascular dementia**: 20-25% of cases
- **Lewy body dementia**: 10-15% of cases
- **Frontotemporal dementia**: 5-10% of cases
- **Mixed dementia**: Multiple pathologies

### Reversible Causes
- **Metabolic**: Hypothyroidism, vitamin B12 deficiency
- **Infectious**: Neurosyphilis, HIV encephalopathy
- **Toxic**: Alcohol, medications, heavy metals
- **Structural**: Normal pressure hydrocephalus, tumors
- **Psychiatric**: Depression ("pseudodementia")

## Alzheimer's Disease

### Overview
- **Most common**: Dementia type worldwide
- **Pathology**: Amyloid plaques and neurofibrillary tangles
- **Progression**: Insidious onset, gradual progression
- **Genetics**: Complex inheritance, some familial forms

### Pathophysiology

#### Amyloid Cascade Hypothesis
- **Amyloid-β (Aβ) accumulation**: Extracellular plaques
- **APP processing**: Abnormal cleavage by β- and γ-secretases
- **Oligomers**: Toxic soluble Aβ species
- **Neurodegeneration**: Downstream effects of amyloid accumulation

#### Tau Pathology
- **Neurofibrillary tangles**: Intracellular tau aggregates
- **Phosphorylation**: Hyperphosphorylated tau protein
- **Microtubule dysfunction**: Impaired axonal transport
- **Spread pattern**: Stereotypical progression through brain regions

#### Neuroinflammation
- **Microglial activation**: Chronic inflammatory response
- **Complement activation**: Inflammatory cascade
- **Cytokine release**: Pro-inflammatory mediators
- **Blood-brain barrier**: Dysfunction and increased permeability

#### Synaptic Loss
- **Synapse degeneration**: Early and significant finding
- **Neurotransmitter deficits**: Acetylcholine, glutamate systems
- **Network disruption**: Altered connectivity patterns
- **Correlation with symptoms**: Best correlates with cognitive decline

### Genetic Factors

#### Familial Alzheimer's Disease (5%)
- **APP**: Amyloid precursor protein mutations
- **PSEN1**: Presenilin-1 mutations (most common)
- **PSEN2**: Presenilin-2 mutations
- **Inheritance**: Autosomal dominant, early onset (<65 years)

#### Sporadic Alzheimer's Disease (95%)
- **APOE**: ε4 allele increases risk, ε2 protective
- **Other genes**: TREM2, CLU, CR1, PICALM
- **Polygenic risk**: Multiple small-effect variants
- **Gene-environment interaction**: Lifestyle modifies genetic risk

### Clinical Presentation

#### Early Stage (Mild)
- **Memory loss**: Recent events, names, conversations
- **Word-finding difficulties**: Tip-of-tongue phenomena
- **Disorientation**: Getting lost in familiar places
- **Judgment problems**: Poor decision-making
- **Mood changes**: Anxiety, irritability, depression

#### Middle Stage (Moderate)
- **Severe memory loss**: Personal history, family members
- **Language problems**: Aphasia, reduced vocabulary
- **Executive dysfunction**: Planning, organizing, sequencing
- **Behavioral changes**: Agitation, wandering, sleep disturbances
- **Functional decline**: Need assistance with daily activities

#### Late Stage (Severe)
- **Profound memory loss**: Recognition of family members
- **Communication loss**: Minimal verbal output
- **Motor symptoms**: Rigidity, gait disturbances, swallowing problems
- **Complete dependence**: Require full-time care
- **Medical complications**: Infections, aspiration, pressure sores

### Atypical Presentations
- **Posterior cortical atrophy**: Visual-spatial symptoms
- **Primary progressive aphasia**: Language-predominant symptoms
- **Frontal variant**: Executive and behavioral symptoms
- **Limbic-predominant**: Memory and behavioral symptoms

## Vascular Dementia

### Overview
- **Second most common**: Dementia type
- **Pathophysiology**: Cerebrovascular disease effects on cognition
- **Subtypes**: Multi-infarct, subcortical, mixed
- **Risk factors**: Cardiovascular disease, diabetes, hypertension

### Pathophysiology
- **Large vessel disease**: Multiple cortical infarcts
- **Small vessel disease**: Subcortical white matter changes
- **Hypoperfusion**: Chronic cerebral hypoperfusion
- **Strategic infarcts**: Key cognitive areas (thalamus, angular gyrus)

### Clinical Features
- **Stepwise progression**: Sudden changes with partial recovery
- **Focal deficits**: Corresponding to vascular territories
- **Preserved insight**: Early stages
- **Executive dysfunction**: Prominent feature
- **Gait abnormalities**: Early finding

### Subtypes

#### Multi-infarct Dementia
- **Multiple strokes**: Cumulative cognitive impact
- **Cortical involvement**: Language, visuospatial deficits
- **History**: Clear strokes or TIAs
- **Imaging**: Multiple cortical infarcts

#### Subcortical Vascular Dementia
- **Small vessel disease**: White matter hyperintensities
- **Executive dysfunction**: Primary cognitive feature
- **Mood changes**: Depression, apathy
- **Motor symptoms**: Parkinsonism, gait disorder

## Dementia with Lewy Bodies

### Overview
- **Third most common**: Dementia type
- **Pathology**: α-synuclein protein aggregates (Lewy bodies)
- **Clinical triad**: Cognitive fluctuations, visual hallucinations, parkinsonism
- **Overlap**: With Parkinson's disease dementia

### Pathophysiology
- **α-synuclein aggregation**: Lewy bodies and Lewy neurites
- **Distribution**: Cortical and subcortical regions
- **Neurotransmitter deficits**: Acetylcholine, dopamine
- **Concurrent pathology**: Often with Alzheimer changes

### Core Clinical Features
- **Cognitive fluctuations**: Varying attention and alertness
- **Visual hallucinations**: Typically well-formed, detailed
- **Parkinsonism**: Bradykinesia, rigidity, gait disturbance
- **REM sleep behavior disorder**: Acting out dreams

### Suggestive Features
- **Neuroleptic sensitivity**: Severe reactions to antipsychotics
- **Autonomic dysfunction**: Orthostatic hypotension, constipation
- **Repeated falls**: Due to parkinsonism and attention fluctuations
- **Syncope**: Transient loss of consciousness

## Frontotemporal Dementia

### Overview
- **Younger onset**: Typically 45-65 years
- **Pathology**: Tau or TDP-43 protein aggregates
- **Genetics**: Strong familial component (40%)
- **Focal atrophy**: Frontal and temporal lobes

### Subtypes

#### Behavioral Variant (bvFTD)
- **Personality changes**: Disinhibition, apathy, loss of empathy
- **Executive dysfunction**: Planning, judgment, problem-solving
- **Compulsive behaviors**: Repetitive, stereotyped actions
- **Dietary changes**: Sweet tooth, overeating

#### Primary Progressive Aphasia
- **Semantic variant**: Word comprehension loss, fluent speech
- **Non-fluent variant**: Agrammatic speech, motor speech apraxia
- **Logopenic variant**: Word retrieval difficulty, phonological errors

### Genetics
- **MAPT**: Tau gene mutations
- **GRN**: Progranulin mutations
- **C9orf72**: Hexanucleotide repeat expansion
- **Other genes**: VCP, CHMP2B, FUS

## Diagnosis

### Clinical Assessment

#### History
- **Cognitive symptoms**: Onset, progression, domains affected
- **Functional decline**: Activities of daily living, work performance
- **Behavioral changes**: Personality, mood, sleep patterns
- **Medical history**: Vascular risk factors, medications, toxins
- **Family history**: Dementia, genetic disorders

#### Physical Examination
- **Neurological exam**: Focal deficits, movement disorders
- **Cardiovascular exam**: Blood pressure, heart rhythm
- **General exam**: Signs of systemic disease

### Cognitive Assessment

#### Screening Tests
- **Mini-Mental State Exam (MMSE)**: 30-point global assessment
- **Montreal Cognitive Assessment (MoCA)**: More sensitive screening
- **Mini-Cog**: Brief 3-minute test
- **Clock drawing test**: Visuospatial and executive function

#### Comprehensive Testing
- **Neuropsychological battery**: Detailed cognitive domains
- **Memory tests**: Immediate, delayed, recognition
- **Executive function**: Trail-making, Wisconsin card sort
- **Language assessment**: Naming, fluency, comprehension

### Laboratory Studies
- **Complete blood count**: Anemia, infection
- **Comprehensive metabolic panel**: Electrolytes, glucose, renal function
- **Thyroid function**: TSH, free T4
- **Vitamin B12 and folate**: Deficiency screening
- **Syphilis serology**: RPR or VDRL

### Neuroimaging

#### Structural Imaging
- **MRI brain**: Preferred imaging modality
- **Atrophy patterns**: Regional volume loss
- **Vascular changes**: White matter hyperintensities, infarcts
- **Other pathology**: Tumors, hydrocephalus, hemorrhage

#### Functional Imaging
- **FDG-PET**: Glucose metabolism patterns
- **SPECT**: Regional blood flow
- **Amyloid PET**: Amyloid plaque burden
- **Tau PET**: Tau pathology distribution

### Biomarkers

#### CSF Biomarkers
- **Amyloid-β42**: Decreased in Alzheimer's disease
- **Total tau**: Increased in neurodegeneration
- **Phospho-tau**: Increased in Alzheimer's disease
- **Ratios**: Improve diagnostic accuracy

#### Blood Biomarkers
- **Plasma Aβ**: Correlates with brain amyloid
- **Plasma tau**: Reflects neurodegeneration
- **Neurofilament light**: General neurodegeneration marker
- **GFAP**: Astrocytic activation marker

### Differential Diagnosis
- **Normal aging**: Mild cognitive changes
- **Mild cognitive impairment**: Intermediate state
- **Depression**: Pseudodementia
- **Delirium**: Acute confusional state
- **Medication effects**: Anticholinergics, sedatives

## Treatment

### Pharmacological Treatment

#### Cholinesterase Inhibitors
- **Donepezil**: 5-10 mg daily, all stages
- **Rivastigmine**: 6-12 mg daily or patch
- **Galantamine**: 16-24 mg daily
- **Mechanism**: Increase acetylcholine availability
- **Benefits**: Modest cognitive and functional improvement
- **Side effects**: Nausea, diarrhea, bradycardia

#### NMDA Receptor Antagonist
- **Memantine**: 10 mg twice daily
- **Mechanism**: Modulates glutamate neurotransmission
- **Indication**: Moderate to severe Alzheimer's disease
- **Benefits**: May slow functional decline
- **Side effects**: Dizziness, headache, confusion

#### Combination Therapy
- **Donepezil + memantine**: FDA-approved combination
- **Rationale**: Different mechanisms of action
- **Evidence**: Modest additional benefit

#### New Therapies
- **Aducanumab**: Controversial amyloid-targeting antibody
- **Lecanemab**: Recently approved anti-amyloid therapy
- **Donanemab**: Investigational anti-amyloid therapy
- **Limitations**: Modest benefits, significant costs, side effects

### Behavioral and Psychological Symptoms

#### Non-pharmacological Approaches
- **Environmental modifications**: Structured, calm environment
- **Behavioral interventions**: Redirection, validation therapy
- **Activity programs**: Music, art, reminiscence therapy
- **Caregiver education**: Understanding and managing behaviors

#### Pharmacological Management
- **Depression**: SSRIs (sertraline, citalopram)
- **Agitation**: Low-dose atypical antipsychotics (if severe)
- **Sleep disorders**: Sleep hygiene, melatonin
- **Anxiety**: Buspirone, low-dose SSRIs

### Non-Pharmacological Interventions

#### Cognitive Interventions
- **Cognitive stimulation**: Group activities, mental exercises
- **Cognitive training**: Specific skill practice
- **Cognitive rehabilitation**: Functional goal-oriented training
- **Reality orientation**: Reorienting to time, place, person

#### Physical Interventions
- **Exercise programs**: Aerobic and resistance training
- **Physical therapy**: Gait training, fall prevention
- **Occupational therapy**: Activities of daily living
- **Speech therapy**: Communication and swallowing

#### Psychosocial Interventions
- **Support groups**: Patient and caregiver groups
- **Counseling**: Individual and family therapy
- **Respite care**: Temporary caregiver relief
- **Day programs**: Structured social activities

### Caregiver Support
- **Education**: Disease understanding, care techniques
- **Training**: Behavioral management, safety strategies
- **Support services**: Respite care, support groups
- **Health monitoring**: Caregiver stress and burden

## Prevention

### Risk Factors

#### Modifiable Risk Factors
- **Cardiovascular**: Hypertension, diabetes, obesity, smoking
- **Lifestyle**: Physical inactivity, poor diet, social isolation
- **Education**: Low educational attainment
- **Hearing loss**: Untreated hearing impairment

#### Protective Factors
- **Education**: Higher educational attainment
- **Physical activity**: Regular aerobic exercise
- **Social engagement**: Active social networks
- **Cognitive activity**: Lifelong learning, mental stimulation
- **Mediterranean diet**: Healthy dietary patterns

### Prevention Strategies

#### Primary Prevention
- **Cardiovascular health**: Blood pressure, diabetes, cholesterol control
- **Lifestyle modifications**: Exercise, diet, smoking cessation
- **Cognitive engagement**: Education, mental stimulation
- **Social connections**: Maintaining relationships

#### Secondary Prevention
- **Early detection**: Screening for mild cognitive impairment
- **Risk factor management**: Aggressive treatment
- **Cognitive interventions**: Training and stimulation
- **Clinical trials**: Investigational preventive treatments

## Complications

### Medical Complications
- **Aspiration pneumonia**: Swallowing dysfunction
- **Urinary tract infections**: Incontinence, catheter use
- **Pressure ulcers**: Immobility, malnutrition
- **Falls and fractures**: Gait instability, cognitive impairment
- **Malnutrition**: Decreased appetite, swallowing problems

### Behavioral Complications
- **Agitation and aggression**: Resistance to care
- **Wandering**: Safety risks, elopement
- **Sleep disturbances**: Day-night reversal, frequent awakening
- **Sundowning**: Evening behavioral deterioration
- **Psychosis**: Hallucinations, delusions, paranoia

### Caregiver Complications
- **Caregiver burden**: Physical and emotional stress
- **Depression**: High rates in family caregivers
- **Health problems**: Neglect of own health needs
- **Financial strain**: Long-term care costs
- **Social isolation**: Reduced social activities

### Legal and Ethical Issues
- **Capacity assessment**: Decision-making ability
- **Advance directives**: End-of-life preferences
- **Guardianship**: Legal protection needs
- **Driving safety**: License restrictions
- **Financial exploitation**: Vulnerability to abuse

## Prognosis

### Disease Progression
- **Alzheimer's disease**: 8-10 years average survival
- **Vascular dementia**: Variable, depends on vascular health
- **Lewy body dementia**: 6-8 years average survival
- **Frontotemporal dementia**: 6-8 years average survival

### Factors Affecting Prognosis
- **Age of onset**: Earlier onset may progress faster
- **Dementia type**: Different progression patterns
- **Comorbidities**: Medical conditions affect survival
- **Social support**: Quality of care influences outcomes

### Stages of Progression
- **Mild**: Independent living with some assistance
- **Moderate**: Increased supervision and care needs
- **Severe**: Complete dependence for all activities
- **End-stage**: Medical complications, hospice care

### Quality of Life Factors
- **Symptom management**: Effective treatment of complications
- **Environmental factors**: Safe, supportive living situation
- **Caregiver quality**: Skilled, compassionate care
- **Healthcare access**: Specialized dementia care

## Key Points

- Dementia is a clinical syndrome of progressive cognitive decline affecting daily functioning
- Alzheimer's disease is the most common cause, characterized by amyloid plaques and tau tangles
- Early diagnosis allows for treatment planning and advance directive completion
- Cholinesterase inhibitors provide modest symptomatic benefit in Alzheimer's disease
- Non-pharmacological interventions are important for managing behavioral symptoms
- Cardiovascular risk factor management may reduce dementia risk
- Caregiver support and education are essential components of care
- Behavioral and psychological symptoms require individualized management approaches
- Prevention strategies focus on modifiable risk factors and healthy lifestyle
- Advance care planning should address future care preferences and goals

## References

1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups. Alzheimers Dement. 2011;7(3):263-269.
2. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.
3. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.